Hepatitis BIt is a serious liver infection that affects millions of people worldwide. Due to improved vaccines against this disease, it has become possible to prevent infection. However, it is important to confirm the immune response of individuals to the vaccine, to determine whether immunity is lost over time and to evaluate serological markers in the diagnosis of the disease. Here’s the point Elecsys® Anti-HBs II test, Hepatitis B surface antigen (HBsAg) counter-community measurement of antibodies quantitatively providing an effective solution.
Quantitative measurement of anti-HBs antibodies
This test consists of hepatitis B virus Anti-HBs antibodies numerically determines. The value obtained as a result of the implementation of the test, the individual Doesn’t gain immunity to hepatitis B virus shows. Before vaccination, after vaccination or immune status can be used to detect the presence of immunity in unknown people. In addition, HBV seroconversion after infection (the immune development of the body) is an effective test in verifying in the laboratory environment.
Clinical Use Area and Target Patient Group
Elecsys® Anti-HBs IIadults, pregnant women and 2 from 21 from age Pediatrics Suitable for. This test, K2-EDTA and K3-EDTA plasma or works with serum samples. Evaluation that immunity after vaccination occurs and does not occur, Identify vulnerable individuals against hepatitis B and other HBV diagnose together with serological tests used for purpose. Especially in cases that show symptoms of hepatitis and cause undetectable, evaluated with other cerological markers differentized diagnosis contributes.
ECLIA Reliable and Fast Results with Technology
Elecsys® Anti-HBs II, Roche“High sensitivity ECLIA (elektrokimiluemia immunooassay) works with technology. Thanks to this technology, the test provides high specificity and repeatability. Ability to work with automation in laboratory environment ECLIA based systems allow accurate and reliable results in clinical decision processes.
cobas Full compliance with e Series Devices
This test, Rochés advanced technology cobas e immunoassay analyzers compatible with. Specifically cobas e 411, e 602, e 601, e 801 and e 402 Working integrated with their devices ensures high efficiency and minimum user intervention. Because the test process is carried out fully automatically, it reduces the laboratory workload and minimizes the risk of human error.
Clinical Importance and Interpretation of the Test
Anti-HBs testgives direct information about the presence of immunity to hepatitis B. Test result reagent It is understood that individuals who have undergone hepatitis B infection earlier and have gained immunity or have developed immunity by responding to vaccine. The negative test resultsindicates that the individual is not immune to hepatitis B and is open to infection. Therefore, the test plays a major role in vaccination decisions and infection control strategies.
